Do the new PV (polycythemia vera) medications such as JAK2 inhibitors benefit patients that do not have a spleen? Dr. Prithviraj Bose of MD Anderson Cancer Center discusses both splenomegaly and splenectomy in PV patients. Listen for his explanation on JAK2 based on the RESPONSE II clinical trial data.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement